webinar register page

Webinar banner
How Blood Technology Is the Future for Gastroesophageal Cancers
Join us in a special edition of the Hope Webinar Series which will include a patient story: Camilla Row and her experience with ctDNA monitoring.

Dr. Dan Catenacci, GI Oncologist will present an overview of the current landscape of assays and what it means exactly. We have invited guest diagnostics industry experts to discuss on the latest developments in the market, and different applications for these technologies.

Our goal is to explaining MRD, ctDNA, RNA, NGS, and other comprehensive biomarker testing. Additionally, discuss the role of liquid biopsies in precision oncology.

This webinar is intended to educate and empower better care management for patients, caregivers, and medical professionals.

Industry Experts from:

MiRXES is a biotechnology company whose mission is to save lives through early, actionable, and personalized diagnoses. Our versatile miRNA detection platform has broad applications for discovery of cancer biomarkers and we are developing a comprehensive portfolio of early detection tests targeting gastric, lung, colorectal, breast, liver and ovarian cancer.

Natera™ is a global leader in cell-free DNA testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health, and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 100 peer-reviewed publications that demonstrate high accuracy. For more information, visit www.natera.com.

Signatera is a custom-built circulating tumor DNA (ctDNA) test for treatment monitoring and molecular residual disease (MRD) assessment in patients previously diagnosed with cancer. Signatera is personalized and tumor-informed, providing each individual with a customized blood test tailored to fit the unique signature of clonal mutations found in that individual’s tumor.

02:02:00

Webinar logo
* Required information
Loading
The information and services provided by Stomach Cancer Awareness Network are for informational and supportive purposes only. They are not intended to be substitutes for professional medical advice, diagnosis, or treatment. The Stomach Cancer Awareness Network does not recommend or endorse any specific medical providers, treatments, or products even though they may be mentioned in this webinar. Always seek the advice of your physician or other qualified medical provider with any questions you may have regarding your medical condition or any information you found on this webinar.

Speakers

Camilla Row
Patient
Camilla is a young mom and wife who was originally diagnosed with stage one stomach cancer in 2018. She had a stomach cancer reoccurrence in 2022 and now has a stage four diagnosis. This is her inspiring story of perseverance.
Dr. Dan Catenacci
GI Oncologist
Dr. Catenacci has experience as an active basic and clinical researcher, focusing on the treatment of gastroesophageal (esophagus, gastroesophageal junction, and stomach) cancers. His bench-to-bedside translational research had overarching goals to validate and improve personalized diagnostics, treatment, immunotherapy, and precision medicine for gastroesophageal cancer and other GI cancers. A major focus of his research was on the use of next-generation sequencing in tumor tissue and blood for the quantification of tumor genetic molecular heterogeneity both between individuals with gastroesophageal cancer, but importantly also within a given individual within one tumor site, and from one tumor site to another, and how this impacts personalized targeted therapeutic approaches. Additionally, Dr Catenacci designed and executed novel clinical trials to implement treatment strategies based on these laboratory and clinical discoveries.
Phillip Munson
US-based Medical Affairs Manager @MiRXES
Phillip Munson is the US-based Medical Affairs Manager for MiRXES and has years of experience in cancer related biomarker discovery. MiRXES is a biotechnology company whose mission is to save lives through early, actionable, and personalized diagnoses. Our versatile miRNA detection platform has broad applications for discovery of cancer biomarkers and we are developing a comprehensive portfolio of early detection tests targeting gastric, lung, colorectal, breast, liver and ovarian cancer.
Dr. Adham Jurdi
Medical Director, Oncology @Natera
Dr. Adham Jurdi is a Board-certified Medical Oncologist who specializes in gastrointestinal malignancies. Prior to joining Natera, Dr Jurdi was the Medical Director at Austin Cancer Center and SUNY Upstate Medical University Cancer Center, as well as being a staff oncologist at the Syracuse VAMC. Throughout his clinical career, he has been involved in GI oncology and precision medicine research. He also launched several multidisciplinary tumor boards, including Austin's first Molecular Tumor Board.